PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine

References

• Ashina M . Migraine. N. Engl. J. Med.383(19), 1866–1876 (2020).
   PubMed Web of Science ®Google Scholar
• Steiner TJ , StovnerLJ , JensenR , UluduzD , KatsaravaZ. Lifting the burden: the global campaign against headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J. Headache Pain21(1), 137 (2020).
   PubMed Web of Science ®Google Scholar
• Steiner TJ , StovnerLJ , KatsaravaZet al. The impact of headache in Europe: principal results of the Eurolight project. J. Headache Pain15(1), 31 (2014).
   PubMed Web of Science ®Google Scholar
• Vo P , FangJ , BilitouA , LaflammeAK , GuptaS. Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain and the United Kingdom. J. Headache Pain19(1), 82 (2018).
   PubMed Web of Science ®Google Scholar
• Stovner LJ , AndréeC. Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J. Headache Pain9(3), 139–146 (2008).
   PubMed Web of Science ®Google Scholar
• Lampl C , ThomasH , StovnerLJet al. Interictal burden attributable to episodic headache: findings from the Eurolight project. J. Headache Pain17, 9 (2016).
   PubMed Web of Science ®Google Scholar
• Tso AR , GoadsbyPJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention?Curr. Treat. Options Neurol.19(8), 27 (2017).
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM , BloudekLM , BeckerWJet al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache53(4), 644–655 (2013).
   PubMed Web of Science ®Google Scholar
• Hepp Z , DodickDW , VaronSFet al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia37(5), 470–485 (2017).
   PubMed Web of Science ®Google Scholar
• Seng EK , RainsJA , NicholsonRA , LiptonRB. Improving medication adherence in migraine treatment. Curr. Pain Headache Rep.19(6), 24 (2015).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , SprengerT. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol.9(3), 285–298 (2010).
   PubMed Web of Science ®Google Scholar
• Hepp Z , DodickDW , VaronSF , GillardP , HansenRN , DevineEB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia35(6), 478–488 (2015).
   PubMed Web of Science ®Google Scholar
• Orlando V , MucherinoS , MonettiVM , TramaU , MendittoE. Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open10(11), e038972 (2020).
   PubMed Web of Science ®Google Scholar
• Diener HC , FörderreutherS , GaulCet al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: addition to the S1 guideline: therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society. Neurol. Res. Pract.2, 11 (2020).
   PubMedGoogle Scholar
• Yuan H , SpareNM , SilbersteinSD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache59(Suppl. 2), 20–32 (2019).
   PubMed Web of Science ®Google Scholar
• AJOVY®, summary of product characteristics. Teva Pharmaceuticals GmbH, Ulm, Germany (2019).
   Google Scholar
• AJOVY®, prescribing information. Teva Pharmaceuticals USA, Inc., North Wales, PA, USA (2020).
   Google Scholar
• Goadsby PJ , SilbersteinSD , YeungPPet al. Long-term safety, tolerability and efficacy of fremanezumab in migraine: a randomized study. Neurology95(18), e2487–e2499 (2020).
   PubMed Web of Science ®Google Scholar
• Ferrari MD , DienerHC , NingXet al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, Phase IIIb trial. Lancet394(10203), 1030–1040 (2019).
   PubMed Web of Science ®Google Scholar
• Dodick DW , SilbersteinSD , BigalMEet al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA319(19), 1999–2008 (2018).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , DodickDW , BigalMEet al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med.377(22), 2113–2122 (2017).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , CohenJM , SeminerioMJ , YangR , AshinaS , KatsaravaZ. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J. Headache Pain21(1), 114 (2020).
   PubMed Web of Science ®Google Scholar
• Lipton RB , CohenJM , BibeauKet al. Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from HALO CM study. Headache60(10), 2444–2453 (2020).
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM , StevanovicDM , OrtegaMet al. No “wearing-off effect” seen in quarterly or monthly dosing of fremanezumab: subanalysis of a randomized long-term study. Headache60(10), 2431–2443 (2020).
   PubMed Web of Science ®Google Scholar
• Buse DC , GandhiSK , CohenJMet al. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. J. Headache Pain21(1), 109 (2020).
   PubMed Web of Science ®Google Scholar
• Kosinski M , BaylissMS , BjornerJBet al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual. Life Res.12(8), 963–974 (2003).
   PubMed Web of Science ®Google Scholar
• Yang M , Rendas-BaumR , VaronSF , KosinskiM. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia31(3), 357–367 (2011).
   PubMed Web of Science ®Google Scholar
• Stewart WF , LiptonRB , WhyteJet al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology53(5), 988–994 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart WF , LiptonRB , KolodnerK , LibermanJ , SawyerJ. Reliability of the Migraine Disability Assessment score in a population-based sample of headache sufferers. Cephalalgia19(2), 107–114 (1999).
   PubMed Web of Science ®Google Scholar
• Lambru G , HillB , MurphyM , TylovaI , AndreouAP. A prospective real-world analysis of erenumab in refractory chronic migraine. J. Headache Pain21(1), 61 (2020).
   PubMed Web of Science ®Google Scholar
• Robblee J , DevickKL , MendezN , PotterJ , SlonakerJ , StarlingAJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache60(9), 2014–2025 (2020).
   PubMed Web of Science ®Google Scholar
• Kanaan S , HettieG , LoderE , BurchR. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia40(13), 1511–1522 (2020).
   PubMed Web of Science ®Google Scholar
• Alex A , VaughnC , RayhillM. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache60(10), 2454–2462 (2020).
   PubMed Web of Science ®Google Scholar
• Sacco S , BendtsenL , AshinaMet al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain20(1), 6 (2019).
   PubMed Web of Science ®Google Scholar